The issue was approved and closed on June 19, 2025, after the company received applications and funds from eligible Qualified Institutional Buyers (QIBs), as per SEBI regulations.
The Fund Raising Committee of Biocon’s board allocated 13.63 crore shares (136,363,635 equity shares of face value ₹5 each) at the final issue price, which includes a premium of ₹325 per share.
The issue price was determined in accordance with Regulation 176(1) of SEBI’s Issue of Capital and Disclosure Requirements (ICDR) Regulations. The final allocations and confirmation notes have also been sent to eligible institutional investors.
Also Read: HSBC retains its positive stance on Biocon citing a key near-term trigger
Biocon had opened the QIP on June 16, 2025 to raise upto ₹4,500 crore. The company said the entire process was completed within regulatory norms and timelines.
Kotak Mahindra Capital, Goldman Sachs (India), and BofA Securities India were advising Biocon on the capital raise, which is aimed at paring down debt and bolstering the Bengaluru-based company’s balance sheet.
Shares of Biocon closed at ₹347.00, up ₹5.00 or 1.46% on the NSE on Thursday.
